Synthetic marijuana drug test expanded to cover new chemicals; aligns with proposed ban of XLR-11 and UR-144.

Now one of the most comprehensive panels available for synthetic cannabinoids (K2/Spice).

SANTA ROSA, Calif., April 18, 2013 - Redwood Toxicology Laboratory (RTL), the government services division of Alere Toxicology, has expanded its urine and oral fluid "K2/Spice" panels. The improved tests detect 19 synthetic cannabinoids, including three recently Emergency Controlled drugs: AKB-48, UR-144 and XLR-11.

As the pioneering laboratory to establish testing for synthesized marijuana, RTL understands that "drug chemists" are quick to change the active ingredients to circumvent federal drug laws. Through vigilant scientific analysis on over 400,000 urine and oral fluid specimens and observed changes to positivity rates, RTL verifies the extensive manufacture and use of many new chemicals.

The Synthetic Drug Abuse Prevention Act signed into law July 2012, bans five classes of synthetic cannabinoids and 15 specific drugs. However, production of new chemicals and distribution methods endure. Products continue to flourish online as veiled herbal incense, potpourri mixtures, and smoke blends. Teens and young adults still turn to these chemicals for the psychoactive effects that mimic highly potent marijuana. The drug also appeals to those wishing to avoid detection when submitting for a standard drug screen.

RTL's updated test panels detect a total of 19 synthetic cannabinoids in urine or oral fluid. The expansion covers 12 next-generation drugs, including eight banned substances (AM-694, JWH-019, JWH-122, JWH-200, JWH-203, JWH-398, MAM-2201, RCS-8), three drugs recently placed under Emergency Schedule 1 (AKB-48, UR-144, and XLR-11), and one next-generation, still legal, compound (AM-1248). The cost of the improved and highly sensitive LC/MS/MS test panels will remain the same.

The requirements to maintain an expanded test are rigorous, involving continual analysis of ever-emerging drugs. Commenting on the recent development, Albert Berger, RTL General Manager and Vice President, said, "Being one of only a few laboratories that offer an expanded test, we take great pride in our service." Berger continued, "Customers that wish to detect an array of designer drugs and have confidence that they are still relevant will greatly benefit from using this test."

Since the development of the original test targeting JWH-018 and JWH-073, RTL has adapted this panel four times to cover the latest chemicals of concern, often in advance of a federal ban. The DEA's recent decision to Emergency Schedule three next-generation drugs proves again that while persistent chemists attempt to circumvent regulation RTL diligently develops methods ahead of a ban.

RTL Technical Director Sumandeep Rana said, "In our testing population (primarily court ordered tests and the drug treatment segment), the average positivity rate for cannabimimetics have remained stable at about 10%." Continued Rana, "If we neglected to update our panels, we'd only see about 1% positivity, and a lot more false-negative results, underscoring how vital it is to target the newest chemical variants."

Laboratory urine and oral fluid analyses have proven to be a substance abuse deterrent for thousands of clients concerned about the proliferation of synthetic drugs. RTL's wealth of expertise, innovation, dependability, and support demonstrates its position as a leader in designer drug monitoring.

About Redwood
Redwood Toxicology Laboratory (RTL) is the government services division of Alere Toxicology and one of the nation's largest drug and alcohol testing laboratories. RTL is dedicated to providing reliable, innovative, and accessible substance abuse screening products and lab test options to help criminal justice and treatment professionals promote wellness, relieve addiction suffering, and restore health. For more information about RTL, please visit

About Alere
By developing new capabilities in near-patient diagnosis, monitoring and health management, Alere enables individuals to take charge of improving their health and quality of life at home. Alere's global leading products and services, as well as its new product development efforts, focus on cardiology, infectious disease, toxicology, diabetes, oncology and women's health. Alere is headquartered in Waltham, Massachusetts. For more information regarding Alere, please visit